ASO GROUP Ltd Purchases New Position in Solventum Corporation $SOLV

ASO GROUP Ltd purchased a new stake in Solventum Corporation (NYSE:SOLV) in the 4th quarter, HoldingsChannel reports. The fund purchased 62,623 shares of the company’s stock, valued at approximately $4,962,000. Solventum accounts for approximately 1.9% of ASO GROUP Ltd’s holdings, making the stock its 8th biggest holding.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Solventum by 5.3% during the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after acquiring an additional 867,837 shares in the last quarter. Independent Franchise Partners LLP grew its stake in shares of Solventum by 27.2% during the third quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after acquiring an additional 2,758,174 shares in the last quarter. State Street Corp grew its stake in shares of Solventum by 1.8% during the third quarter. State Street Corp now owns 6,220,271 shares of the company’s stock valued at $454,080,000 after acquiring an additional 112,261 shares in the last quarter. Davis Selected Advisers grew its stake in shares of Solventum by 12.7% during the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock valued at $492,880,000 after acquiring an additional 702,461 shares in the last quarter. Finally, Boston Partners grew its stake in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after acquiring an additional 959,543 shares in the last quarter.

Solventum Stock Performance

Shares of NYSE SOLV opened at $79.23 on Friday. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The firm’s 50-day moving average price is $72.21 and its two-hundred day moving average price is $75.23. Solventum Corporation has a 52-week low of $62.38 and a 52-week high of $88.20. The stock has a market capitalization of $13.72 billion, a P/E ratio of 9.71, a P/E/G ratio of 1.25 and a beta of 0.69.

Solventum (NYSE:SOLV) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter last year, the company posted $1.34 earnings per share. Solventum’s revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, sell-side analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SOLV. Stifel Nicolaus lowered their target price on Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Wells Fargo & Company lowered their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th. BTIG Research restated a “buy” rating and set a $89.00 target price on shares of Solventum in a research note on Wednesday, May 6th. Finally, Wedbush began coverage on Solventum in a research note on Friday, May 15th. They set an “outperform” rating and a $94.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Solventum currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.25.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.